If intimacy has quietly changed since menopause — less desire, less comfort, a little more distance — you are not imagining it, and you are not too old to want closeness back. Wanting to feel like yourself, and close to your partner, is a perfectly ordinary human wish at 47 or 58 or beyond.
This article walks through what an independent provider actually reviews when desire and comfort shift after menopause: which hormonal and health markers matter, how local (vaginal) and whole-body (systemic) approaches differ, and what the evaluation involves. It is educational and not medical advice; only a licensed provider can evaluate you and decide whether any option is appropriate.
First, the part no one says out loud: this is common
The years around and after menopause bring a real shift in hormones — most notably a decline in estrogen, with changes in androgens (including testosterone and DHEA) as well. These changes can affect both desire and the physical comfort of intimacy [1][2].
One specific, well-described pattern is the genitourinary syndrome of menopause (GSM) — vaginal dryness, thinning and reduced elasticity of tissue, irritation, and discomfort during sex. GSM is driven largely by lower estrogen acting on tissues that depend on it, and unlike hot flashes, it tends to persist rather than fade over time [2][3]. Desire is more layered: it involves hormones, but also sleep, mood, stress, medications, relationship dynamics, and overall health. That is exactly why a thoughtful evaluation looks at the whole picture rather than a single number.
What a provider reviews: the conversation comes first
Before any lab, an independent provider typically starts with history. Expect questions about when the change began, whether discomfort or low desire (or both) is the main concern, your menstrual/menopause timeline, current medications (some antidepressants and blood-pressure drugs affect desire), sleep, mood, and your general health.
This matters because professional guidelines describe low desire as a clinical concern mainly when it is persistent and personally distressing to you — your experience, in your words, is the starting point, not a lab value [4]. You do not have to arrive with the right vocabulary. "Things changed and I want to understand why" is enough.
Source: [3] Genitourinary Syndrome of Menopause (GSM) — The Menopause Society, [4] Global Consensus Position Statement on the Use of Testosterone Therapy for Women — Endocrine Society / Journal of Clinical Endocrinology & Metabolism
What a provider reviews: the markers
There is no single "libido test." Instead, a provider may consider a panel that helps rule things in or out and check for safety. Commonly reviewed markers can include:
- Estradiol (estrogen) — the primary estrogen affected by menopause, relevant to vaginal/tissue symptoms and overall menopausal status [1][2].
- FSH — often elevated after menopause; helps confirm menopausal status when the picture is unclear [1].
- Testosterone (total and sometimes free) — androgens decline gradually with age; professional guidelines discuss testosterone specifically in the context of distressing low desire in postmenopausal women, while emphasizing careful evaluation [4][5].
- DHEA-S — a precursor hormone the body can convert into other sex hormones; it is also relevant because a vaginal DHEA product exists for certain menopausal symptoms [5][6].
- Thyroid (TSH), iron studies, glucose/A1c, and a general metabolic review — because fatigue and low desire can have non-hormonal drivers worth catching.
The Endocrine Society notes that a blood testosterone level does not reliably diagnose low desire on its own, and that testosterone measurement is used mainly to set a safe baseline and to monitor, not to make the diagnosis from a number alone [4]. The point of the panel is context and safety — not a verdict.
Source: [1] Menopause — StatPearls (NCBI Bookshelf), [4] Global Consensus Position Statement on the Use of Testosterone Therapy for Women — Endocrine Society / Journal of Clinical Endocrinology & Metabolism, [5] Androgen and DHEA changes across the menopause transition — NIH/NICHD review (PubMed)
Local vs. systemic: two different problems, two different tools
One of the most useful distinctions a provider draws is where the issue lives.
Local (vaginal) approaches — aimed at comfort
When the main concern is dryness, irritation, or pain with intimacy from GSM, approaches that act locally on vaginal tissue are often considered first. These include non-hormonal vaginal moisturizers and lubricants, and prescription options such as low-dose vaginal estrogen and vaginal DHEA (prasterone), which act primarily on local tissue with limited whole-body exposure [2][3][6]. The North American Menopause Society describes low-dose vaginal estrogen as a standard, well-studied approach for GSM symptoms [3].
Systemic approaches — broader, and more individualized
When symptoms extend beyond the vagina — for example, hot flashes alongside intimacy concerns — systemic menopausal hormone therapy may enter the conversation. This is a more individualized decision that weighs your age, time since menopause, personal and family history (including breast cancer and cardiovascular risk), and preferences [1][2]. For distressing low desire specifically, some guidelines discuss testosterone for postmenopausal women as an option to consider after a careful evaluation, while stressing that data are limited and ongoing monitoring is needed [4][5].
Importantly, there is no FDA-approved testosterone product for women in the United States; any such use is off-label and is a clinical judgment made by a licensed provider [4]. This is one reason an honest evaluation matters more than a quick prescription.
What about compounded options?
You may see compounded hormone preparations marketed for menopause and desire. A few things are worth knowing plainly: Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Whether a compounded or FDA-approved option is appropriate — or whether a non-hormonal route fits you better — is a decision for your independent provider based on your evaluation.
Safety: the questions that protect you
A careful provider treats safety as the foundation. Estrogen-containing therapies are individualized around cardiovascular and breast-health history; the landmark Women's Health Initiative research is part of why providers weigh timing, age, and personal risk rather than applying a one-size answer [7]. For androgen-related options, monitoring matters because effects and side effects depend on the person [4][5]. None of this is meant to discourage you — it is exactly the kind of attention that lets you pursue closeness with confidence rather than worry.
You are allowed to want this
Desire and comfort are part of health, not a luxury you age out of. Bringing this up is not vain or embarrassing; it is the same as raising any other change in how your body works. Whether the answer turns out to be local comfort, a systemic conversation, a non-hormonal route, or simply ruling things out — the goal is the same one you already named: to feel like yourself, and close to your partner, again.
Where Velri fits
Velri is a technology and coordination company — not a medical practice. We help organize the parts so the process feels less daunting: coordinating lab work, connecting you with an independent, licensed provider who reviews your history and results and decides whether any option is appropriate for you, and — only if something is prescribed — coordinating with an independent licensed pharmacy. A prescription is never guaranteed; that decision belongs entirely to the independent provider. This article is educational and is not medical advice. For an evaluation specific to you, speak with a licensed provider.
